الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 76 |  |  |
| | | from | 76 | | |
Abstract
Alopecia areata (AA) is an autoimmune condition characterized by inflammation-induced hair loss. It can affect the scalp, the beard, or even the whole body. The first line of treatment in patchy AA is triamcinolone acetonide (TrA) administered intralesionally.
Platelet-rich plasma (PRP) is a relatively new, presently evolving treatment modality that is playing an increasingly important role in the field of dermatology. More recently, the role of PRP in promoting hair growth has also been investigated.
We conducted this study to compare the therapeutic efficacy of intralesional injection of TrA alone versus intralesional TrA with intralesional PRP in treatment of AA.
This was a comparative observational study conducted on patients who were recruited from the Dermatology Outpatient Clinic of the Alexandria Main University Hospital to compare the efficacy of intralesional TrA alone vs intralesional TrA and intralesional PRP in treating patchy AA. A total of 30 patients with patchy AA with two non-adjacent patches were enrolled in the study and divided into two groups; group I, including AA patches that were treated with intralesional TrA alone (2.5 mg/ml), and group II, including AA patches that were treated with intralesional TrA (2.5 mg/ml) and intralesional PRP (2–3 ml). The interval between treatment sessions was 4 weeks, and the treatment period continued for 3 months.
In the current study, there were 24 males (80%) and 6 females (20%). Their ages ranged from 22 to 62 years with a mean of 37.0 ± 11.39 years.
In the present work, the mean duration of the disease was 11.03 ± 9.47 months. The majority of patients had AA patches in the scalp (83.3%), followed by beard (10%) and mustache (6.7%). Half of the patients presented with 1st attack and the other half presented with 2nd attack. Family history was positive in 20% of patients , 16.7% of patients had autoimmune diseases and 33.3 % had nail involvement.
Trichoscopic findings (yellow dots, black dots, exclamation marks, and broken hair) in our study showed a statistically significant reduction at the end of sessions (12 weeks) in both groups.
Before treatment, the most frequent dermoscopic feature was yellow dots, representing 80% followed by black dots, broken hair, and exclamation marks, representing 36.7%, 30%, and 23.3%, respectively. While after treatment, only 2 patches (6.7%) showed broken hairs.
In the present study, patients who were treated with combined TrA and PRP showed more improvement than patients who were treated with TrA alone after 4, 8, and 12 weeks as regards Macdonald hull scoring and regrowth scale. In addition, there was a significant improvement in each group regarding Macdonald hull scoring and regrowth scale over time.